Axsome Therapeutics Stock News

In the last trading session, 1.03 million shares of the Axsome Therapeutics Inc. (NASDAQ:AXSM) were traded, and its beta was 2.18. Most recently the companys share price was $35.80, and it changed around $0.21 or 0.59% from the last close, which brings the market valuation of the company to $1.34B. AXSM currently trades at a Lets Talk About How Axsome Therapeutics Inc. (NASDAQ: AXSM) Stock Is Doing. Read More »

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie purchased 527 shares of the firms stock in a transaction that occurred on Thursday, November 18th. The stock was acquired at an average price of $35.50 per share, for a total transaction of $18,708.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, []

Man Group plc trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 80.9% during the second quarter, Holdings Channel reports. The firm owned 7,994 shares of the companys stock after selling 33,907 shares during the quarter. Man Group plcs holdings in Axsome Therapeutics were worth $539,000 at the end of the most recent []

Axsome Therapeutics (NASDAQ:AXSM) had its price target reduced by Mizuho from $55.00 to $51.00 in a research note released on Thursday, The Fly reports. They currently have a buy rating on the stock. Several other equities analysts have also recently commented on AXSM. SVB Leerink reduced their target price on Axsome Therapeutics from $75.00 to []

Axsome Therapeutics, Inc. (NASDAQ:AXSM)s stock price traded up 6.6% during mid-day trading on Friday following insider buying activity. The company traded as high as $38.79 and last traded at $37.95. 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. The stock had previously closed at []

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been assigned an average rating of “Buy” from the thirteen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price target among brokerages […]

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2021 Results - Earnings Call Transcript

The company provided its third-quarter update.

Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time

Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the compa

$100 million now available upon the potential FDA approval of AXS-05

These stocks are expected to put up big gains in a short amount of time.

Optimism among investors is growing for the possible approval of the biotech's MDD drug.

This biotech is down, but it isn't out just yet.